HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Ahluwalia, R. Articles by Marsh, S. Search for Related Content PubMed PubMed Citation Articles by Ahluwalia, R. Articles by Marsh, S. Related Collections Molecular Diagnostics and Genetics

Use of Pyrosequencing to Detect Clinically Relevant Polymorphisms in Dihydropyrimidine Dehydrogenase

¹ Washington University School of Medicine, Division of Oncology, St. Louis, MO 63110

^aaddress correspondence to this author at: Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8069, St. Louis, MO 63110; fax 314-362-3764, e-mail smarsh@im.wustl.edu

The first 300 words of the full text of this article appear below.

Common human diseases, such as cancer, have been associated with multiple types of variation in the genome, including sequence repeats and deletions and single-nucleotide polymorphisms (SNPs) (1). Of these, SNPs are the most abundant in the human genome (2)(3). As a result of the efforts of many groups (4), an estimated 5 million SNPs are now deposited in public databases (5), providing a resource for determining how genomic variation affects human biology. Building on this work, many groups have shown that drug response is also influenced by genomic variation (6). Multiple SNPs have been identified that have a major impact on response to chemotherapy (7)(8)(9)(10)(11); it is therefore necessary to have rapid and efficient SNP evaluation techniques to analyze genes that influence chemotherapy response.

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the three-step degradation of uracil to ß-alanine (12). This is the only endogenous pathway for production of the neurotransmitter ß-alanine (13). DPD also degrades >80% of the anticancer agent 5-fluorouracil (5-FU), a pyrimidine analog used to treat colorectal cancer, and limits the oral absorption of the drug (13). DPD activity is found to be highest in liver and mononuclear cells, but it is also present in most other human tissues (14).

Variation in DPD activity can lead to nonbeneficial physiologic conditions. A complete absence of DPD has been associated with the hereditary metabolic disorder thymine-uraciluria (9). This is characterized by mental retardation and is sometimes accompanied by other neurologic disorders, such as microcephaly, motor retardation, and autism (9). In addition, decreased DPD activity leads to severe toxicity from 5-FU even when typical . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904. [Abstract] [Full Text] [PDF]

				E. Rouits, M. Boisdron-Celle, A. Dumont, O. Guerin, A. Morel, and E. Gamelin Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients Clin. Cancer Res., August 1, 2004; 10(15): 5151 - 5159. [Abstract] [Full Text] [PDF]